is combination therapy for chronic hepatitis c toxic for cardiac function?
نویسندگان
چکیده
background many types of cardiovascular complications such as; cardiac arrhythmias, impaired cardiac function, myocardial ischemia and decreased left ventricular function, have been attributed to interferon therapy. objectives the aim of this study was to evaluate the effects of combination therapy pegylated interferon and ribavirin on left ventricular systolic and diastolic functions in patients with a chronic hepatitis c infection. patients and methods a total of 120 patients, eligible for hepatitis c virus (hcv) treatment with pegylated interferon and ribavirin, were included in this study. all patients underwent a full cardiovascular baseline examination including; detailed medical history, thorough clinical examination, 12 lead electrocardiogram (ecg), and echocardiography. a cardiac evaluation was performed at the beginning and six months after starting combination therapy. results no significant changes regarding cardiac symptoms including; shortness of breath, cough, palpitations, chest pain and hypertension, were found during or six months after starting the combined therapy. ecg findings showed statistically non-significant decreases in the qt interval, while corrected qt showed statistically non-significant increases six months after beginning combined therapy, when compared to their values before treatment. also with regard to the echocardiography findings, there was no statistically significant difference found between any of the echocardiography parameters six months after starting combined therapy compared to their values before treatment. conclusions the results of our study suggest that, combination therapy does not cause a significant deterioration in cardiac function in patients with a chronic hepatitis c infection, and it may be used safely in patients without cardiac disease.
منابع مشابه
Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function?
BACKGROUND Many types of cardiovascular complications such as; cardiac arrhythmias, impaired cardiac function, myocardial ischemia and decreased left ventricular function, have been attributed to interferon therapy. OBJECTIVES The aim of this study was to evaluate the effects of combination therapy pegylated interferon and ribavirin on left ventricular systolic and diastolic functions in pati...
متن کاملEFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملCost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
OBJECTIVE To explore the expected long-term health and economic outcomes of telaprevir (TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that demonstrated substantially increased sustained virologic response (SVR) compared with PR alone in adults with chronic genotype 1 hepatitis C virus (HCV) and compensated liver disease in the Phase III studies ADVANCE (treatment-naïve patients)...
متن کاملSome Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We read with great interest the recently published article by Almawardy et al entitled " Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function? " (1). They skillfully evaluated 120 cases with hepatitis C virus infections treated with a combination proto...
متن کاملefficacy and safety of combination therapy of interferon-alpha 2b plus ribavirin for chronic hepatitis c
introduction: the aim of this study is to assess the therapeutic efficacy and safety of a particular brand of ifn alpha (pdferon b®) in combination with ribavirin (rlba) on iranian patients with chronic hepatitis c (chc). the addition of riba to the standard treatment with interferon (ifn) alpha led to an improvement in sustained virologic response (svr) from less than 20% with ifn monotherapy ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۲، شماره ۸، صفحات ۰-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023